Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926143 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03926143 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 9 participants.
The verdict
NCT03926143, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.
Interventions
- DRUG BAY94-9343 (Anetumab ravtansine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2022-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926143
The ClinicalTrials.gov registry entry for NCT03926143 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY94-9343 (Anetumab ravtansine) is the first listed.
NCT03926143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926143 about?
NCT03926143 is a clinical study titled "A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies". The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.
What is the current status of trial NCT03926143?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2019-06-03. Estimated completion is 2022-05-18.
What interventions are being tested in trial NCT03926143?
The interventions under investigation include: BAY94-9343 (Anetumab ravtansine) (DRUG).
Who is sponsoring clinical trial NCT03926143?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.